Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Ipilimumab Yervoy伊匹单抗

Ipilimumab was approved by the FDA on March 25, 2011 for the treatment of unresectable or metastatic melanoma. Sales in 2015 were US$1.13 billion.
Ipilimumab is a monoclonal antibody that binds to cytotoxic T lymphocyte-associated antigen (CTLA-4) and prevents the binding of CTLA-4 to its ligands (CD80 and CD86). Blocking CTLA-4 can increase T Cell activity and proliferation ability.

Share: